Seattle Genetics: $552 Million Follow-On

Seattle Genetics, a company developing cancer treatments, in its $552 follow-on offering. The proceeds will help commercialize flagship drug Adcetris and expand the biotech's pipeline.

Related Contacts
Chadwick Mills Partner, San Francisco
Charlie Kim Partner, San Diego
Related Practices & Industries

Capital Markets Life Sciences